Lundbeck

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for neurological diseases. The company's proprietary pipeline includes several product candidates, notably LP352, a next-generation 5-HT2C agonist intended for treating developmental and epileptic encephalopathies. Additionally, Longboard is evaluating LP143, a full agonist of the cannabinoid type 2 receptor, which targets conditions such as amyotrophic lateral sclerosis and Parkinson's disease, as well as LP659, a selective modulator for multiple central nervous system neuroinflammatory disorders. Longboard Pharmaceuticals aims to optimize pharmacology and pharmacokinetics across its drug candidates, enhancing therapeutic outcomes for patients with rare neurological conditions. The company was incorporated in 2020 and was previously known as Arena Neuroscience, Inc.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Abide Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapeutics targeting serine hydrolases, a class of enzymes that has significant potential for treating various diseases. Founded in 2011, the company operates from its headquarters in San Diego, California, and has an additional office in Princeton, New Jersey. Abide Therapeutics employs a unique platform that facilitates the efficient identification, development, and validation of small-molecule inhibitors that selectively target these enzymes. This innovative approach aims to address serious diseases with substantial unmet medical needs by enhancing the understanding of the roles serine hydrolases play in human health and disease. In 2019, Abide Therapeutics became a subsidiary of H. Lundbeck A/S, furthering its capacity for drug development.

Prexton Therapeutics is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It focuses on developing innovative drugs for Parkinson's disease and other brain disorders, utilizing a unique scientific approach that integrates molecular, behavioral, and chemistry technologies. The company targets metabotropic glutamate receptors, specifically mGluR4 and mGluR3, to create novel therapeutic compounds. Prexton Therapeutics aims to enhance the quality of life for patients by providing alternatives to traditional dopaminergic treatments, enabling quicker initiation of therapy and improved medical outcomes. As of March 2018, Prexton operates as a subsidiary of H. Lundbeck A/S.

BenevolentAI is a clinical-stage company specializing in AI-enabled drug discovery and development. By leveraging its advanced AI platform alongside scientific expertise and laboratory capabilities, the company aims to create novel drug candidates that demonstrate a higher likelihood of clinical success compared to traditional approaches. The Benevolent Platform supports a robust pipeline that includes over 20 drug programs, encompassing all stages from target discovery to clinical studies. Additionally, BenevolentAI collaborates with major pharmaceutical companies and leading research and charitable institutions to enhance its research efforts. The company is headquartered in London, with research facilities in Cambridge and an office in New York.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company based in Charlotte, North Carolina, that focuses on acquiring, developing, and commercializing products for various human diseases. The company is primarily engaged in developing therapeutic agents for the treatment of symptomatic neurogenic orthostatic hypotension and related conditions. Additionally, it is working on prescription products aimed at addressing multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. Chelsea Therapeutics is advancing two key clinical-stage projects: droxidopa for symptomatic neurogenic orthostatic hypotension and a portfolio of non-metabolized antifolate compounds targeted at rheumatoid arthritis and other conditions.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The firm is pioneering a new mechanism for modulating the N-methyl-D-aspartic acid receptor (NMDAR), which distinguishes its approach from existing treatments. Researchers at Naurex have developed a new class of drugs known as glycine-site functional partial agonists (GFPAs), designed to safely modulate the NMDAR. The company's drug development pipeline includes its first-generation molecule, GLYX-13, and a second-generation series, NRX-1050, along with additional compounds derived from its platform of novel NMDAR modulators. Naurex aims to address significant unmet needs in psychiatry and neurology through these advancements.

Proximagen is a publicly traded neuroscience research company specializing in drug development for neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. The company offers therapeutic drug development services, leveraging its expertise in medicinal chemistry, biology, and pharmacokinetics to create novel therapeutics targeting central nervous system diseases and inflammation.

Laboratoire Elaiapharm S.A., a pharmaceutical contract manufacturing organization, provides pharmaceutical development, manufacturing, and commercial and clinical packaging services. Its development services include feasibility studies, pre-formulation and formulation, process development and validation, galenic development, process optimization, reformulation and life cycle management, development and validation of analytical methods, ICH stabilities, and regulatory support and documentation. The company also engages in manufacturing solid dose, liquid, sterile, and non-sterile products, such as tablets, powders, hard capsules, vials, ampoules, bottles, drops, and active pharmaceutical ingredients. In addition, it offers primary and secondary packaging, clinical packaging, late stage customization, labeling, artworks management, and logistics and distribution services; and dossiers development and licensing services.

Ovation Pharmaceuticals, founded in 2000 and acquired by Lundbeck in 2009, operates as a subsidiary focused on developing, manufacturing, and distributing prescription pharmaceuticals for underserved patient populations. The company specializes in late-stage products in the central nervous system (CNS) and hematology/oncology sectors, as well as hospital-based pharmaceuticals. Ovation Pharmaceuticals is dedicated to addressing the needs of specific physician specialty markets by acquiring under-marketed products and leveraging its sales expertise to enhance their reach. Its portfolio includes a variety of medications, such as methamphetamine hydrochloride and vigabatrin, that are utilized in the treatment of various diseases and disorders, with a strong emphasis on meeting the needs of focused patient groups. The company’s products are marketed in multiple countries, ensuring a broad distribution network.

Saegis Pharmaceuticals is dedicated to developing medications aimed at treating behavioral disorders linked to central nervous system (CNS) diseases. The company has a robust pipeline targeting cognitive dysfunction related to conditions such as Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. By focusing on therapeutics for patients experiencing memory loss and cognitive deficits due to aging, psychiatric disorders, and brain injuries, Saegis Pharmaceuticals seeks to address significant challenges in mental health and cognitive health. Founded in 1999, the company is headquartered in Half Moon Bay, California.

Synaptic Pharmaceutical Corporation develops human receptor-targeted drug design technology. The Company offers technology which is used to discover and clone the genes that code for human receptor subtypes that may be associated with specific disorders.